Quadriga BioSciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1
Completed
- Conditions
- AstrocytomaBrain MetastasesGastric CancerKidney CancerMelanomaSarcomaBladder CancerBreast CancerColorectal CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Quadriga Biosciences, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04430842
- Locations
- 🇦🇺
Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia
🇦🇺St George Private Hospital, Kogarah, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath